LICENSE AGREEMENTLicense Agreement • March 29th, 2007 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances) • Pennsylvania
This License Agreement (“Agreement”) is made by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at 3160 Chestnut Street, Suite 200, Philadelphia, Pennsylvania 19104-6283 (“Penn”) and Targeted Genetics Corporation, a corporation organized and existing under the laws of Washington (“Targeted”), having a place of business at 1100 Olive Way, Suite 100, Seattle, Washington 98101.
AMENDMENT NO. 3 TO EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • March 29th, 2007 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 3 to the exclusive sublicense agreement (the “Amendment”) is made and entered into as of March 9, 2007 by and between Alkermes, Inc., a Pennsylvania corporation with its principal offices at 88 Sidney Street, Cambridge, MA 02139 (hereinafter referred to as “Alkermes”), and Targeted Genetics Corporation, a Washington corporation with its principal offices at 1100 Olive Way, Suite 100, Seattle, Washington 98101 (hereinafter referred to as “Targeted”).
Amendment No. 1 to OTT License Agreement Number L-086-2000/0Ott License Agreement • March 29th, 2007 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances)
This is the First Amendment to the OTT License Agreement Number L-086-2000/0 dated May 21, 2004 by and between the United States Public Health Service as represented by the Office of Technology Transfer, National Institutes of Health having offices at 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804 (“PHS”) and Targeted Genetics Corporation (“TGC”), a corporation of Washington having a principal place of business at 1100 Olive Way, Suite 100, Seattle, WA 98101(hereinafter, First Amendment).
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT--EXCLUSIVE COVER PAGEPatent License Agreement • March 29th, 2007 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the "Agreement", consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) and/or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Modifications), Appendix E (Benchmarks), and Appendix F (Commercial Development Plan). The Parties to this Agreement are:
LICENSE AGREEMENTLicense Agreement • March 29th, 2007 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances) • Pennsylvania
THIS AGREEMENT (the “Agreement”) is made and is effective December 5, 2006, (the “Effective Date”) by and between Targeted Genetics Corporation, a corporation having a principal place of business at 1100 Olive Way, Suite 100, Seattle, Washington 98101 (“TGC”), and Amsterdam Molecular Therapeutics B.V. (“AMT”), a corporation having a principal place of business at Meibergdreef 61, 1100 DA Amsterdam, The Netherlands.
